Patents by Inventor Lilach CHEN ZELTSBURG

Lilach CHEN ZELTSBURG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTRACELLULAR DELIVERY COMPOSITIONS
    Publication number: 20240148886
    Abstract: Protein conjugates comprising a protein carrier comprising polyethylenimine, a payload that interacts with an intracellular target and a linker are provided. Pharmaceutical composition comprising the protein conjugates as well as methods of using and producing the protein conjugates are also provided.
    Type: Application
    Filed: October 18, 2023
    Publication date: May 9, 2024
    Inventors: Orit SHILOVITZKY, Lilach CHEN ZELTSBURG, Rozi Ravit UZAN GUETA, Ayala LEWKOWICZ, Yossi GOTTFRIED, Rotem FAYGENBOIM-ORNAI, Motti HAKIM, Yair SAPIR, Ilana MANDEL, Tehila BEN-MOSHE, Avidor SHULMAN
  • Modified DNase and uses thereof
    Patent number: 11814657
    Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: November 14, 2023
    Assignee: Protalix Ltd.
    Inventors: Lilach Chen Zeltsburg, Ilya Ruderfer, Avidor Shulman, Liat Fux, Yulia Ugortsev, Hagit Neta, Sivan Gelley, Elad Lavee Laviad, Yoseph Shaaltiel
  • SHEDDING BLOCKING AGENTS WITH INCREASED STABILITY
    Publication number: 20230144459
    Abstract: Agents comprising at least two moieties separated by a linker, wherein a first moiety binds mCD28 on a surface of a cell and inhibits proteolytic cleavage of the mCD28 and wherein a second moiety increases stability of the first moiety are provided. Methods of treating cancer and improving immunotherapy comprising administering the agents are also provided.
    Type: Application
    Filed: March 11, 2021
    Publication date: May 11, 2023
    Inventors: Motti HAKIM, Anna FRIDMAN-DROR, Ilana MANDEL, Tehila BEN-MOSHE, Yair SAPIR, Avidor SHULMAN, Lilach Chen ZELTSBURG, Ayala LEWKOWICZ
  • MODIFIED DNASE AND USES THEREOF
    Publication number: 20220106578
    Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 7, 2022
    Applicant: Protalix Ltd.
    Inventors: Lilach CHEN ZELTSBURG, Ilya RUDERFER, Avidor SHULMAN, Liat FUX, Yulia UGORTSEV, Hagit NETA, Sivan GELLEY, Elad LAVEE LAVIAD, Yoseph SHAALTIEL
  • Modified DNase and uses thereof
    Patent number: 11225648
    Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: January 18, 2022
    Assignee: Protalix Ltd.
    Inventors: Lilach Chen Zeltsburg, Ilya Ruderfer, Avidor Shulman, Liat Fux, Yulia Ugortsev, Hagit Neta, Sivan Gelley, Elad Lavee Laviad, Yoseph Shaaltiel
  • MODIFIED DNASE AND USES THEREOF
    Publication number: 20180112201
    Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
    Type: Application
    Filed: January 4, 2016
    Publication date: April 26, 2018
    Inventors: Lilach CHEN ZELTSBURG, Ilya RUDERFER, Avidor SHULMAN, Liat FUX, Yulia UGORTSEV, Hagit NETA, Sivan GELLEY, Elad LAVEE LAVIAD, Yoseph SHAALTIEL